Prevention of Recurrence With Cordyceps Sinensis in Mycobacterium Avium Complex Pulmonary Disease
In plain words A Phase 4 study of cordyceps in people 18 to 75, run by Bin Cao. It plans to enroll about 300 people at 6 sites, none in the US.
Who it lists and where
Who the trial lists, as registered
Lists people 18 to 75. Conditions: Mycobacterium Avium Complex Pulmonary Disease.
- Patients voluntarily participate in the study and sign the informed consent form.
- Age between 18 and 75 years, inclusive; gender unrestricted.
- Confirmed diagnosis of MAC (Mycobacterium avium complex) lung disease according to either the 2020 ATS/IDSA guidelines or the Chinese Guideline for Diagnosis and Treatment of Nontuberculous Mycobacterial Disease (2020 edition).
- Completed the recommended treatment regimen for nodular-bronchiectatic MAC lung disease (macrolide + ethambutol + rifampin, with minimum 12-month duration) per the above guidelines within 3 months prior to screening; Fully completed the…
2 more inclusion criteria and the exclusion criteria are on the listing.
What it tests, as registered
cordyceps sinesis capsule; cordyceps sinesis capsule placebo
Registered summary
The goal of this clinical trial is to learn if cordyceps sinesis capsule (Bailiing Capsule) works to prevent the recurrence of microbiologically cured mycobacterium avium complex pulmonary disease in adults. The main questions it aims to answer are: Does cordyceps sinesis capsule (Bailiing Capsule) prevents the recurrence of mycobacterium avium complex pulmonary disease in adults? Researchers will compare cordyceps sinesis capsule (Bailiing Capsule) to a placebo (a look-alike substance that contains no drug) to see if cordyceps sinesis capsule helps to prevent the recurrence of mycobacterium… The full summary is on the listing.
Where, as registered
No US site; China (6).